Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 8/20 | 0.47 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.47 |
| ▸ | HTR2B known ✓ | P41595 | 5/20 | 0.47 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.40 |
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.38 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.38 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.38 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.38 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | HTR7 known ✓ | P34969 | 2/20 | 0.38 |
| ▸ | HTR6 known ✓ | P50406 | 2/20 | 0.38 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.37 |
| ▸ | HTR1E known ✓ | P28566 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16322736 | 0.98 | HTR2C (0.48) | HTR2CHTR2AHTR2BPIM1PIM2 | |
| SCHEMBL15282036 | 0.83 | AKR1C3 (0.50) | PIM1PIM2AKR1C3AKR1C1PROKR1 | |
| Tert-Butyl Formate SCHEMBL27552576 | 0.81 | TDP1 (0.37) | HTR2CHTR2AHTR2BPIM1PIM2 | |
| Hydrochloric Acid SCHEMBL4881733 | 0.80 | KMT2A (0.47) | HTR2CHTR2AHTR2BPIM1PIM2 | |
| Hydrochloric Acid SCHEMBL4891394 | 0.80 | IKBKB (0.47) | HTR2CHTR2AHTR2BPIM1PIM2 | |
| Hydrochloric Acid SCHEMBL14721151 | 0.80 | HTR2C (0.43) | HTR2CHTR2AHTR2BPIM1PIM2 | |
| Hydrochloric Acid SCHEMBL2256641 | 0.79 | HTR2C (0.50) | HTR2CHTR2BPIM1PIM2SIGMAR1 | |
| SCHEMBL17684333 | 0.79 | AKR1C3 (0.52) | PIM1PIM2AKR1C3AKR1C1PROKR1 | |
| Hydrochloric Acid SCHEMBL6293547 | 0.78 | CYP1A2 (0.50) | HTR2CHTR2AHTR2BPIM1PIM2 | |
| SCHEMBL14730978 | 0.78 | MAOA (0.43) | HTR2CHTR2AHTR2BPIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10335402-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-02 | — | — | US | disclosed |
| US-10308635-B2 | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| US-10208016-B2 | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-19 | — | — | US | disclosed |
| US-20180251445-A1 | 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS | TAKEDA PHARMACEUTICALS CO (JP) | 2018-09-06 | — | — | US | disclosed |
| EP-3010900-B1 | 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-03 | — | — | EP | disclosed |
| US-20170340621-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED GASTROINTESTINAL DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-30 | — | — | US | disclosed |
| EP-3218363-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED GASTROINTESTINAL DISORDERS | Takeda Pharmaceutical Company Limited (JP) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016075457-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED GASTROINTESTINAL DISORDERS | TAKEDA CAMBRIDGE LIMITED (GB) | 2016-05-19 | — | — | WO | disclosed |
| US-20160122317-A1 | 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-05 | — | — | US | disclosed |
| EP-3010900-A1 | 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS | Takeda Pharmaceutical Company Limited (JP) | 2016-04-27 | — | — | EP | disclosed |
| WO-2014202999-A1 | 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2014-12-24 | — | — | WO | disclosed |
| US-20080300276-A1 | Heterocyclic Carboxylic Acide Amide Derivatives | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-12-04 | — | — | US | disclosed |
| EP-1771437-A1 | NEW HETEROCYCLIC CARBOXYLIC ACID AMIDE DERIVATIVES | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006010969-A1 | NEW HETEROCYCLIC CARBOXYLIC ACID AMIDE DERIVATIVES | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251445-A1 | 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS | GIPR, PROKR1, PROKR2 | HTR2C 200/4885HTR2A 128/4885HTR2B 176/4885 |
| US-20160122317-A1 | 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS | GIPR, PROKR1, PROKR2 | HTR2C 200/4885HTR2A 128/4885HTR2B 176/4885 |
| US-20080300276-A1 | Heterocyclic Carboxylic Acide Amide Derivatives | HCAR2, GRIN1, HCAR1 | HTR2C 372/4885HTR2A 686/4885HTR2B 663/4885 |
| US-10308635-B2 | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors | GIPR, PROKR1, PROKR2 | HTR2C 200/4885HTR2A 128/4885HTR2B 176/4885 |
| US-10335402-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders | PROKR1, PROKR2, GIPR | HTR2C 213/4885HTR2A 135/4885HTR2B 215/4885 |
| US-20170340621-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED GASTROINTESTINAL DISORDERS | PROKR1, PROKR2, GIPR | HTR2C 213/4885HTR2A 135/4885HTR2B 215/4885 |
| US-10208016-B2 | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors | GIPR, PROKR1, PROKR2 | HTR2C 200/4885HTR2A 128/4885HTR2B 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.